6.1 TURBT Technique & Pathological Staging

6.1 TURBT Technique & Pathological Staging

Transurethral resection of bladder tumour (TURBT) serves as both the definitive diagnostic procedure and the initial therapeutic intervention for non-muscle-invasive bladder cancer (NMIBC). The quality and completeness of the initial TURBT profoundly influence oncological outcomes: an inadequate resection predisposes to early recurrence, disease understaging, delayed radical treatment, and compromised cancer-specific survival.

---

1. Surgical Goals & Preoperative Assessment

The fundamental goals of TURBT are:

1. Complete Macroscopic Resection: Removal of all visible papillary tumours. Biopsy suspicious flat mucosa to diagnose CIS rather than attempting deep resection of every abnormal flat area.
2. Accurate Pathological Staging: Procurement of representative tissue specimens containing sufficient underlying detrusor muscle (muscularis propria) to reliably differentiate non-muscle-invasive disease (Ta, T1, Tis) from muscle-invasive bladder cancer (T2 or higher).
3. Histological Grading & Characterization: Providing adequate, non-cauterized tissue to assess histological subtype, variant features, depth of lamina propria invasion, and the presence of lymphovascular invasion (LVI).

Bimanual Examination Under Anesthesia (EUA)

A structured bimanual examination (one hand on the lower abdomen, gloved index finger in the rectum for men or vagina for women) must be conducted under full muscle relaxation before introducing the resectoscope, and repeated immediately after completing resection.

• No palpable mass: Does not exclude muscle invasion or microscopic perivesical extension. T2 is muscle-invasive; T3a is microscopic perivesical invasion and is not organ-confined.
• Palpable or fixed mass: Suggests locally advanced disease; fixation to the pelvic wall raises concern for T4b. Interpret EUA with pathology and imaging, because examination can under- or overstage disease.

---

2. Resection Techniques: Fractionated vs En Bloc Resection

A systematic inspection of the entire urothelial surface must precede resection, evaluating the anterior wall, bladder dome, posterior wall, lateral walls, trigone, ureteric orifices, bladder neck, and the prostatic urethra in men (using both 30-degree and 70-degree optics).

Fractionated (Separate-Jar) Resection

Fractionated resection represents the traditional standard technique, particularly indicated for exophytic lesions larger than 1.5–2 cm:

• Exophytic Papillary Component: The bulk of the papillary mass is resected flush with the surrounding mucosal plane and submitted in Container A (Superficial/Exophytic).
• Deep Muscular Base: Dedicated cold-cup or loop resection biopsies are obtained from the underlying muscular bed beneath the tumor pedicle and submitted in Container B (Deep Muscle Base).
• Peripheral Margins: Radial biopsies surrounding the perimeter of the tumor base are submitted separately in Container C (Peripheral Edges).

En Bloc Resection of Bladder Tumour (ERBT)

En bloc resection involves a circumferential incision of healthy mucosa around the tumor (with a 2–5 mm macroscopic safety margin) followed by retro-tumoral dissection through the deep submucosa and superficial detrusor layer to excise the tumor as a solitary, intact specimen containing mucosa, lamina propria, and muscularis propria.

• Energy Modalities: Monopolar/bipolar electrical current, Thulium:YAG laser, Holmium:YAG laser, or hydro-dissection.
• Oncological Advantages: Preserves architecture for margin assessment and T1 substaging while avoiding tumour fragmentation. Thermal damage depends on the energy and technique; reliable superiority in recurrence/progression over well-performed conventional TURBT is not established across all settings.
• Limitations: Restricted to lesions typically $\le$ 3 cm in diameter and accessible anatomical locations (relative technical difficulty at the extreme anterior wall or bladder dome).

---

3. The Detrusor Muscle Mandate

The presence of detrusor muscle (muscularis propria) in the resection specimen is the primary surrogate marker of surgical resection quality in TURBT.

• The muscularis propria consists of thick, robust, eosinophilic smooth muscle bundles that are histologically distinct from the thin, discontinuous fibers of the muscularis mucosae found within the lamina propria.
• Clinical Significance: Absence of detrusor muscle in the pathology specimen precludes definitive distinction between T1 disease and muscle-invasive T2 disease. Residual tumour and understaging are more likely when muscle is absent; their rates vary with initial stage, technique and cohort. Absence of muscle does not itself prove muscle invasion.
• Exception: EAU exempts Ta LG/G1 tumours from the routine detrusor requirement. Absence of muscle alone is not an indication for repeat TURBT in Ta LG/G1 or primary CIS; other indications, especially incomplete resection, still apply. The exception is not confined to a solitary primary Ta lesion.

---

4. Intraoperative Complications & Crisis Management

The Obturator Nerve Reflex

Resection of tumors situated on the lateral bladder walls frequently triggers the obturator nerve reflex. The obturator nerve (derived from L2–L4 anterior rami) courses along the lateral pelvic sidewall, immediately adjacent to the inferolateral bladder wall near the obturator canal.

• Mechanism: Electrical current from monopolar resectoscopes conducts through the thin, distended bladder wall, directly depolarizing the nerve and provoking sudden, violent contraction of the thigh adductor muscles (adductor longus, brevis, and magnus).
• Consequence: Involuntary thigh adduction drives the active cutting loop deeply through the bladder wall, resulting in extensive bladder wall perforation, obturator vessel laceration, or extravesical tumor seeding.
• Prevention and Mitigation:
  1. General Anesthesia with Complete Neuromuscular Blockade: Administration of non-depolarizing neuromuscular blocking agents (e.g., rocuronium with train-of-four monitoring) abolishes motor endplate transmission. Spinal anesthesia alone does not reliably prevent a jerk from direct peripheral obturator stimulation.
  2. Selective Obturator Nerve Block: Infiltration of local anesthetic around the obturator nerve in the obturator canal using ultrasound guidance or a peripheral nerve stimulator.
  3. Bipolar Energy & Laser En Bloc: Bipolar current returns locally, but evidence that it prevents obturator jerk is conflicting; do not use it as a substitute for appropriate block or relaxation. Laser resection avoids electrical nerve stimulation.
  4. Minimal Bladder Distension: Maintaining low bladder volume prevents lateral wall thinning and keeps the wall away from the pelvic brim.

Bladder Perforation Management

Bladder perforation occurs in up to 5% of TURBT procedures, categorized anatomically into extraperitoneal and intraperitoneal injuries.

---

5. Enhanced Endoscopic Imaging

White-light cystoscopy can miss lesions, particularly flat CIS. Enhanced techniques improve detection: EAU cites pooled PDD sensitivity of 92% versus 71% for white light at patient level. Better detection does not guarantee improved recurrence outcomes in every trial.

Photodynamic Diagnosis (PDD / Blue-Light Cystoscopy)

• Principle: Intravesical instillation of hexaminolevulinate (HAL, Hexvix) is performed 1 hour prior to surgery via a urethral catheter. Neoplastic urothelial cells preferentially accumulate photoactive porphyrins (specifically protoporphyrin IX) after metabolism of HAL through the porphyrin pathway.
• Optical Detection: Illumination with blue light (wavelength 380–450 nm) excites protoporphyrin IX, causing neoplastic tissue to emit vivid red/pink fluorescence against a dark blue background of normal urothelium.
• Clinical Utility: Improves detection, particularly CIS and additional papillary lesions. Several meta-analyses support reduced recurrence, but results are inconsistent and a large UK randomized trial found no three-year recurrence benefit. PDD is an adjunct to good resection and adjuvant treatment.
• False-Positive Causes: Inflammation, recent TURBT, and the first three months after BCG can cause false-positive fluorescence.

Narrow-Band Imaging (NBI)

• Principle: Optical filter technology that narrows the emitted white light into two discrete wavelengths: 415 nm (blue), which matches the optical absorption band of superficial capillary hemoglobin, and 540 nm (green), which penetrates deeper into submucosal venous plexuses.
• Clinical Utility: Strongly contrasts hypervascular neoplastic structures (which appear dark brown or green) against the pale pink normal mucosa without requiring exogenous photosensitizer instillation. Improves lesion detection; overall randomized recurrence results have been inconsistent, with benefit reported in selected low-risk tumours.

---

6. Histopathological Staging & Dual Grading Systems

Accurate pathological staging under the UICC TNM9 classification (2025), used in EAU 2026 defines non-muscle-invasive bladder cancer:

• Ta: Non-invasive papillary carcinoma confined entirely to the urothelial layer; the basement membrane remains intact.
• T1: Tumor has invaded the subepithelial connective tissue (lamina propria) but does NOT penetrate the muscularis propria. T1 substaging by histo-anatomic or micrometric methods has prognostic value, but there is no universally optimal system; specify the method rather than treating T1a/b as formal TNM categories.
• Tis / CIS: Carcinoma in situ: a flat, non-invasive, high-grade intraurothelial neoplasm. Despite lacking invasion beyond the basement membrane, CIS is cytologically malignant, exhibits high genomic instability, and has substantial progression risk: EAU cites approximately 54% progression to muscle-invasive disease without treatment.

WHO Grading Systems: 1973 vs 2004/2016/2022

EAU recommends WHO 2004/2022 grading and, when available, a hybrid classification incorporating WHO 1973. The schemes overlap rather than convert one-to-one:

Modern papillary categories are PUNLMP, LG carcinoma and HG carcinoma. CIS is always high grade. Grade alone does not supply a universal progression percentage: stage, CIS, tumour burden and treatment also matter. Retain both grading labels when reported and use the system required by the risk model.

---

7. Second-Look TURBT (Re-TURBT)

Second-look TURBT consists of a formal repeat transurethral resection performed within 2 to 6 weeks after the primary procedure, before risk-adapted induction therapy. This does not exclude an otherwise indicated immediate postoperative chemotherapy instillation after a safe, uncomplicated initial TURBT.

Rationale and Evidence Base

Repeat resection identifies residual tumour and occult muscle invasion, and provides prognostic information even after an apparently complete first resection. EAU cites an older T1 systematic review with 51% persistence and 8% understaging, versus a contemporary review with 31.4% residual disease and 2.8% upstaging. Rates vary with population and resection quality; these are not fixed risks for every T1 patient. Repeat TURBT can improve recurrence-free survival and BCG outcomes; a universal progression or cancer-specific survival benefit is not established.

---

8. TURBT Surgical Checklist & Second-Look Indications

Systematic TURBT Surgical Checklist

1. Pre-Resection Review: Review cross-sectional imaging (CT/MRI urography); confirm negative urine culture; ensure patient positioning in dorsal lithotomy without nerve compression.
2. EUA: Bimanual palpation before resection to assess baseline bladder wall induration or pelvic fixation.
3. Diagnostic Pan-Cystoscopy: Systematic inspection of all mucosal surfaces using 30° and 70° lenses; inspect ureteral orifices and prostatic urethra; evaluate lesion size, number, morphology, and mucosal architecture (employ PDD/NBI if available).
4. Resection Execution: Fractionate exophytic bulk, base, and margins; implement obturator prevention maneuvers for lateral walls; avoid over-distension.
5. Specimen Management: Submit base specimen in a separate container labeled "Deep Muscle Base".
6. Hemostasis & Completion: Meticulous bipolar/monopolar coagulation of bed; post-resection EUA; verify clear irrigant return; place 3-way catheter.

Mandatory Indications for Second-Look TURBT (Within 2–6 Weeks)